Adalimumab Improves Hematologic Abnormalities in HS Patients
Hidradenitis Suppurativa (HS) patient receiving adalimumab (Humira, AbbVie) show improvements in anemia, thrombocytosis, and leukocytosis, and these improvements can be seen in clinical responders and nonresponders, according to post hoc analyses of two phase 3 trials published in JAMA Dermatology. The new findings build on a previous study in a smaller cohort of HS patients that […]